Cadila Healthcare Limited announced today that the USFDA inspected its Active Pharmaceutical Ingredients (API) manufacturing facility at Dabhasa, the group's largest API manufacturing site, from 7th to 11th October 2019. This was a CGMP audit and a pre-approval inspection (PAI). At the end of the inspection, no observation (483) is issued.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.230.7 as compared to the previous close of Rs. 232.1. The total number of shares traded during the day was 36673 in over 459 trades.
The stock hit an intraday high of Rs. 234.95 and intraday low of 228.5. The net turnover during the day was Rs. 8440447.